TARGET AUDIENCE
This activity is intended for medical oncologists, hematologists, hematology-oncology fellows and other healthcare providers involved in the treatment of hematologic cancers.

OVERVIEW OF ACTIVITY

Did FIRE-3 study results change in any way your off-protocol practice?

Will the results of the Phase III FIRE-3 study comparing first-line FOLFIRI/bevacizumab to FOLFIRI/cetuximab in patients with KRAS wt metastatic colorectal cancer (mCRC) in any way change your practice?

Which EGFR Ab preferred 1^st as Tx for mCRC? Ever use other EGFR Ab later?

Which EGFR antibody do you usually use first in the treatment of mCRC?

Do you usually use the other EGFR antibody at a later point in treatment?

Tx 60 yo w/ liver mets, questionable resectablility, 18 mo after adj FOLFOX?

What treatment approach would you most likely recommend for a 60-year-old patient with KRAS wt colon cancer who presents 18 months after adjuvant FOLFOX with 4 bilateral liver lesions that are questionable in terms of resectability but may be operable if a response is achieved?

1^st-line Tx 60 yo w/ unresectable mets 1 y after adj FOLFOX? Pt age at which you don’t want to use bev?

What is your usual recommendation for first-line therapy for a 60-year-old patient who presents with widespread, unresectable metastases (PS = 0) 12 months after completion of adjuvant FOLFOX for Stage III KRAS wild-type (wt) colon cancer?

The patient had fared well on adjuvant FOLFOX except for minimal peripheral neuropathy that resolved in 6 months.